Claremont, CA (PRWEB) April 25, 2014
Synedgen announced today the continuation of funding for a significant wound care program sponsored by the Defense Advanced Research Projects Agency (DARPA) to develop a new class of technologically innovative wound cleansers. These products will more effectively rinse dirt and debris from a combat wound than is possible with current treatments in the pre-hospital environment. The rinse contains Synedgen’s patented polysaccharides that are derivatives of biocompatible polymers commonly used in wound care products.
Battlefield wounds are historically embedded with contaminating dirt and debris that if left in place can lead to serious wound complications that impair wound healing. However, due to the austere nature of the battlefield environment, the volume of saline or water required for complete cleansing is logistically impossible on the battlefield. Other cleansing products are not stable in the conditions encountered.
Synedgen’s product is designed for use immediately after wounding as a cleansing irrigation and for continued rinsing at each dressing change to moisten and protect wound beds. Unlike traditional wound rinses, Synedgen’s product is effective at small volumes so it can be easily stored in a medic bag with minimal impact on size or weight constraints.
“We have worked with DARPA bring treatment options for our soldiers closer to point of injury. This new product meets the medical and tactical guidelines for combat care,” stated Synedgen President Shenda Baker.
“Historically many battlefield innovations have had tremendous application to civilian health issues. Although Synedgen initially devised this product to help address the critical need for an effective wound rinse for use by soldiers, millions of civilian traumatic wounds could also benefit from our rinse,” added Synedgen CEO Dr. William Wiesmann.
This award leverages previous Synedgen wound care research programs and will help accelerate the commercialization of Synedgen’s wound care portfolio to bring these products to the market.
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for wound care and for therapies to treat inflammation, damage or infection at pulmonary, oral and gastrointestinal surfaces. Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s website at http://www.synedgen.com.